Cirena Launches High-Purity Long RNA to Accelerate CRISPR and Genome-Editing Research

Breakthrough technology delivers 100–400nt RNA with exceptional purity, enabling faster design cycles and improved editing precision

3 February 2026 -- Colorado, US -- Cirena, pioneers in long and ultra-long, high purity RNA synthesis for gene editing and functional genomics, today announced its public launch following successful delivery of high-quality long RNA to leading academic and pharmaceutical research teams across the U.S., Europe, and Japan.

As CRISPR and prime editing applications advance, researchers are increasingly turning to longer guide RNAs and related constructs to boost editing efficiency and reduce off target effects. Historically, obtaining long RNA meant stitching shorter oligos together, investing significant time in purification, or waiting months for delivery—delays that slow innovation. Cirena eliminates these bottlenecks by rapidly producing long RNA with uncompromised quality, enabling scientists to iterate faster and achieve more precise outcomes.

“As RNA science evolves, researchers are eager to unlock the potential of longer gRNAs for improved editing precision,” said Marv Caruthers, Co-Founder of Cirena. “Cirena enables this exploration by delivering high quality long RNA rapidly, thus eliminating the delays that have historically slowed innovation.”

“While many great companies reliably deliver short RNA, producing long RNA without compromising integrity is notoriously difficult,” commented John Rinn, LincSwitch CEO. “Cirena proved that they can reliably deliver 150nt RNA with exceptional quality across the U.S., enabling our team to confidently advance experiments without delays.”

Cirena’s proprietary technology maintains sequence integrity for demanding CRISPR and functional genomics workflows. The company’s streamlined operations reduce turnaround times, allowing researchers to accelerate gRNA, pegRNA, and related designs. With proven logistics and reliable global delivery, Cirena supports academic, pharma, and biotech teams working on CRISPR base and prime editing, oncology research, vaccine development, and gene regulation studies.

About Cirena
Cirena provides long and ultra-long, high purity RNA for researchers in therapeutics, gene editing, and functional genomics. The company’s proprietary technology -developed at the University of Colorado Boulder by the teams of Prof. Marvin Caruthers (co founder: Amgen, Applied Bioscience) and Dr. Douglas Dellinger (CU Boulder, Agilent) - enables rapid turnaround of 100+ nt RNA with exceptional purity. Cirena is headquartered at the BioFrontiers Institute at the University of Colorado Boulder. Researchers can learn about Cirena’s early customer program or request evaluation materials at www.cirena.com or by contacting RNAtechsupport@cirena.com. Cirena RNA products are intended for research use only.